However, the proportions of tested patients with colon and lung cancers with KRAS mutation were slightly higher than published data, perhaps in part reflecting the referral pattern in our Phase I Program, which may be affected by the availability of MEK inhibitor trials. This evidence concerns the gene MAP2K7 and lung cancer.